OneAscent Financial Services’s Sarepta Therapeutics SRPT Stock Holding History

OneAscent Financial Services’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,540	Closed	-$263K	–	160
2020 Q4	$263K	Sell	1,540 -1,706	-53%	-$253K	0.28%	87
2020 Q3	$456K	Buy	3,246 +574	+21%	+$87.2K	0.24%	82
2020 Q2	$428K	Sell	2,672 -380	-12%	-$51.7K	0.29%	73
2020 Q1	$299K	Sell	3,052 -1,458	-32%	-$167K	0.23%	82
2019 Q4	$582K	Buy	+4,510	New	+$455K	0.32%	48
2019 Q3	–	Sell	-3,255	Closed	-$495K	–	161
2019 Q2	$495K	Buy	+3,255	New	+$396K	0.34%	49

Other funds holding SRPT

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

OneAscent Financial Services's SRPT Position: Q1 2021 in Review

OneAscent Financial Services sold out of Sarepta Therapeutics (SRPT) in Q1 2021, closing a stake of 1,540 shares — an estimated $263K sold.

OneAscent Financial Services first reported a position in SRPT in Q2 2019 and held it in 6 quarters. The position peaked at $582K in Q4 2019. 366 funds tracked by Wall St. Rank hold SRPT as of Q1 2021.

OneAscent Financial Services reported no remaining Sarepta Therapeutics position as of Q1 2021 after selling out during the quarter.
OneAscent Financial Services sold 1,540 Sarepta Therapeutics shares in Q1 2021, an estimated $263K.
OneAscent Financial Services first reported a position in Sarepta Therapeutics in Q2 2019 and held it in 6 quarters.
OneAscent Financial Services's Sarepta Therapeutics position peaked at $582K in Q4 2019.
366 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2021.

Based on OneAscent Financial Services's 13F filing for Q1 2021, filed 27 Apr 2021.